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Response to ‘‘Rank Reversal in Indirect Comparisons’’ by Norton et al.To the Editor – Norton et al. [1] point out that the risk ratio (RR),
the risk difference (RD), and the odds ratio (OR) may lead to
different rankings of treatment alternatives when combining
trials with different baseline risks in indirect comparisons. We
do not dispute this conclusion, but we disagree with the way in
which the authors attribute this problem to indirect compari-
sons. The issue can be clarified by careful consideration of the
objectives of both pairwise meta-analysis and indirect compar-
isons, and the assumptions made in evidence synthesis.Assumptions Underlying Indirect Comparisons
Indirect comparison meta-analysis [2,3] is part of a family of
evidence synthesis methods that includes direct pairwise meta-
analysis [4] and network meta-analysis [5–8]. The latter allows
the combination of both direct and indirect evidence. The key
assumption underlying all these models is that the trials are
exchangeable, which, put simply, means that they all measure
the same underlying relative effects, or effects drawn from a
common distribution [9]. Exchangeability implies that direct and
indirect evidence are consistent, and thus that indirect compar-
isons are valid [9]. All meta-analytic estimates, whether ‘‘fixed
effect’’ or ‘‘random effects,’’ are weighted averages of the study-
specific relative effects [10]. This is also true of the estimates
from network meta-analysis [11]. This, in turn, tells us that the
exchangeability assumptions can be correct only if the treatment
effects are given on a specific linear additive scale. Thus, choos-
ing between the (log) OR, (log) RR, or RD as a scale of measure-
ment is not a matter of selecting a ‘‘summary statistic’’ on the
basis of ease of interpretation or convenience, but one of choos-
ing the most appropriate statistical model for the data at hand.
Note that an analysis on the (log) RR can be carried out either for
the number of subjects experiencing an event or for the number
of subjects not experiencing an event and that these two models
make incompatible assumptions. If the appropriate measure-
ment scale is not the one desired for interpretation, a transfor-
mation can be applied after evidence synthesis [12].
In brief, to carry out a meta-analysis on any scale assumes
that the observed effects are linearly additive and that the trials
are exchangeable on that scale. Obviously, this condition cannot
hold for all the different scales at the same time! This is clearly
illustrated by isoquant plots in Figure 1. That is not to say that
rank reversal could not happen, but that if it did happen it would
be because a data set either fails to meet the exchangeability
assumptions required for meaningful synthesis on any scale orial support: Gert van Valkenhoef was supported bbecause the wrong scale of measurement has been chosen. It is
well known that in pairwise meta-analysis, there is seldom
sufficient data to determine the choice of the appropriate scale
on purely statistical grounds [13], and it is interesting that
network meta-analysis may enable such an empirical assess-
ment [12].Indirect Comparisons for Decision Making
In practice, one could observe a rank reversal on different scales
only if the absolute response rates for each treatment vary from
trial to trial. Rank reversal is not a discrete phenomenon because
the ranking of treatments based on the results of a meta-analysis
is inherently uncertain. Thus, even if the point estimate shifts
from one side of the ‘‘no effect’’ line to another, this need not be
relevant if the confidence interval around it is wide. The degree of
between-trial variation in absolute response rates has to be quite
extreme for relevant rank reversal to be observed. In fact, it has
been suggested that such variation in the absolute response rates
is, in itself, potentially a sign that the exchangeability assump-
tion is not being met [14]. Thus, in practice, the rank reversal
phenomenon is unlikely to be observed unless the data set
violates the assumptions required for sensible synthesis or
unless the data set is so sparse that rank reversals happen
because of sampling error.
Setting this aside, consider the scale of measurement issue
from a practical decision-making perspective. Suppose that in
population 1 the response rates are 0.5% for treatment A, 10% for
treatment B, and 50% for treatment C. This corresponds to
ORAB¼22:1,ORBC¼9,ORAC¼199,
RDAB¼0:095,RDBC¼0:40,RDAC¼0:495:
Suppose now that the scale on which we obtain linearity is
the log(OR) and that in population 2 the absolute response rate is
35% for treatment A. This would mean that we would expect to
see 92.3% response rate on treatment B and 99.1% on treatment C
in population 2. Note that whether we choose a population with
response rate 0.5% or 35% on treatment A, we do not see any rank
reversal. The problem arises if we choose the wrong scale, such
as the RD, and then compare A and B in population 2 (a 57.3%
difference) but compare A and C in population 1 (a 49.5%
difference). Use of the wrong scale then leads to the false
conclusion that B is better than C.
The example illustrates the importance of choosing the scale
on which effects are additive. We see, however, the issue asy the Escher project (T6-202), a project of the Dutch Top Institute
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Fig. 1 – Isoquants for the risk difference (RD), the risk ratio (RR) of events, the RR of nonevents, and the odds ratio (OR).
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trials and generalize them to other situations, and not especially
to indirect comparisons. For example, consider the position of
an investigator who had observed just the effect of A and B in
population 1, and who had assumed additivity on the RD scale.
If this investigator then had to predict the response on B in
patients with a response rate of 35% on A, he or she would
predict 44.5%, seriously underestimating the real response rate
of 92.3% on B. Especially in decisions involving trade-offs
between multiple outcomes, such as benefit-risk or cost-effec-
tiveness, this difference could be as important as a rank
reversal.
Of course, before embarking on such a hazardous prediction,
one would hope that investigators would first ask themselves
whether it is reasonable to expect the same effect size (on
whatever scale) in two populations that are clearly completely
different! There must, after all, be some limits on the possibility of
generalizing treatment effects, which are at the same time the
limits of between-study exchangeability and valid synthesis.
What is strange is that there appears to be very little in theprocess of literature identification and systematic review that is
specifically designed to deliver the assumptions on which gen-
eralizability depends.Conclusions
Indirect comparisons and network meta-analysis are being
increasingly used to make coherent decisions when there are
more than two alternatives [15,16]. Norton et al.’s article is to be
welcomed: in common with a number of recent publications
[17–19], it creates a greater awareness and understanding of what
these methods can and cannot do, and draws attention to the
assumptions underlying the statistical models that are being
fitted.
While the growing use of these multitreatment comparison
methods is quite appropriately raising interest and aware-
ness in the fundamental assumptions being made, there has
perhaps not been a corresponding awareness that these
exact same assumptions apply to pairwise meta-analysis, and
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 4 9 – 4 5 2 451indeed to any process for making valid generalizations based on
evidence.
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1246–1253.Response about Rank ReversalTo the Editor—We thank van Valkenhoef and Ades [1] for their analysis [3–6]. This observation does not lessen the importance of
comments on our article about rank reversal [2] and for raising
several important issues. Their letter reminds readers about the
growing importance of meta-analyses in clinical decision making,
and its potential value to synthesize findings across multiple studies.
While our comments in this response focus on issues related to
meta-analysis, it is important to note that rank reversal is a general
phenomenon whose importance extends beyond meta-analysis.
Van Valkenhoef and Ades’ main point is that indirect compar-
ison meta-analyses assume exchangeability, meaning that all
trials measure the same underlying relative effects on the same
measure (typically risk difference, risk ratio, or odds ratio). Their
conclusion is that the choice of measure (or scale) is derived from
nature and is not a matter of choice. A statistical model
estimated by using one measure is inherently incompatible with
models estimated on another.
We agree with the technical point that the assumption of
exchangeability means that the treatment effect can be homo-
geneous on at most one measure (risk difference, risk ratio, or
odds ratio). As they point out, others have made this observation
as the literature has struggled to understand the importance of
heterogeneous treatment effects in indirect comparison meta-accounting for rank reversal in practice.
Because researchers never know which measure, if any, is
constant in nature, one could in principle use statistical tests to
compare measures. Cochran’s Q statistic [7] and DerSimonian and
Laird’s [8] Q statistic are used to measure the existence of hetero-
geneity. Higgins and Thompson’s I2 statistic measures the degree of
heterogeneity [9]. Conceivably, these tests can identify the condi-
tions under which the assumption of exchangeability is maintained.
There are several reasons these statistical tests are challen-
ging in practice. First, while exploring heterogeneity among
studies included in a meta-analysis has become common [8],
the comparison of heterogeneity between various measures is
not. Unfortunately, making decisions based on these statistical
tests is difficult, in part because the literature does not identify
what acceptable thresholds should be. Most meta-analyses do
not compare across measures. Even when tests of heterogeneity
indicate an appropriate measure, making decisions based solely
on these statistical tests without considering empirical evidence
is not advised [10]. So, while theory suggests that a single measure
will be revealed, in practice this information is not easily deter-
mined and should rely on context as well as statistics.elationships to disclose.
